Revolutions Medical Corporation Begins International Rollout With South American Distributor Agreement

CHARLESTON, SC--(Marketwire - December 16, 2009) - Revolutions Medical Corporation (“RevMed” or the “Company”) (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that it has forged a distribution partnership for the RevVac safety syringe in South America, one of the world’s largest syringe markets. Following its recent RevVac volume manufacturing process launch, RevMed is quickly executing the next phase of its business plan: to create immediate brand awareness, and open distribution channels to key syringe markets worldwide.

To immediately secure access to South America, RevMed has signed a distribution agreement with Libra International, LTD (“Libra”). Libra is a specialist healthcare consultancy that works in partnership with companies seeking to establish operations in South America. A partnership between experienced British and South American healthcare executives, Libra can demonstrate a lengthy track record of success in the South American healthcare system. Libra also has expertise in global sourcing, in-licensing and the pursuit of contracts with private investors and government agencies.

“Now that we have begun the RevVac Safety Syringe volume manufacturing process, we are quickly moving to lay the foundation for the global distribution of our finished product,” stated Revolutions Medical CEO Ron Wheet. “The number of inquiries we have already received from interested parties around the world has exceeded expectations ten-fold, and it stands us in great stead as we begin taking orders in the second quarter of 2010. Libra’s depth of both experience and relationships in South America well positions RevMed in this sizable and rapidly growing market. We believe that their representation of the RevVac safety syringe will help ensure maximum exposure and rapid market penetration.”

Commented Libra Commercial Director Nick Ogle, “Safety syringe sales currently represent a relatively small percentage of the $2 billion South American syringe market -- quite simply, they have been too expensive. But more governments now realize the critical issue of needle stick injuries and spreading blood-borne diseases, and they are looking at introducing legislation that makes the use of safety syringes mandatory. The rising opportunity for a high quality, cost-effective syringe is thus enormous. We believe the RevVac auto-retract safety syringe is just this product. It can be manufactured at a cost approximately equal to that of a traditional high-end disposable syringe. RevMed has achieved this with no loss in quality or mode of action; the RevVac combines improved ease of operation and enhanced safety through simplicity of design. In our opinion the RevVac is the best safety syringe on the market, and we are delighted to be working with RevMed. We look forward to taking their innovative and best-in-class product to the South American market in 2010.”

To be added to the Revolutions Medical investor email list, please email justin.davis@cirrusfc.com with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook -- visit www.facebook.com/RevMed.

About Revolutions Medical Corporation (www.revolutionsmedical.com)

RevMed’s products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite’s functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet: http://content.stockpr.com/rmcp/files/RMCP_-_Fact_Sheet_09-09-09.pdf

CEO Ron Wheet Audio Interview: http://ir.stockpr.com/revolutionsmedical/media-center/view/33/

RevVac Demo Video: http://www.revolutionsmedical.com/videos/revac_directions_final.wmv

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.